A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
Fiche publication
Date publication
mai 2016
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERNIER-CHASTAGNER Valérie, Dr MIRJOLET Céline, Pr NOEL Georges, Pr TRUC Gilles
Tous les auteurs :
Truc G, Bernier V, Mirjolet C, Dalban C, Mazoyer F, Bonnetain F, Blanchard N, Lagneau É, Maingon P, Noël G
Lien Pubmed
Résumé
To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients with glioblastoma.
Mots clés
Adult, Aged, Antineoplastic Agents, Alkylating, administration & dosage, Brain Neoplasms, drug therapy, Combined Modality Therapy, Dacarbazine, administration & dosage, Female, Glioblastoma, drug therapy, Humans, Male, Maximum Tolerated Dose, Middle Aged, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated
Référence
Cancer Radiother. 2016 May;20(3):193-8